Navigation Links
SciClone Announces ZADAXIN and SCV-07 Abstracts Accepted at ASCO

SAN MATEO, CA — April 27, 2007 — SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that the following abstracts have been accepted for the Annual Meeting of the American Society of Clinical Oncology in Chicago, Illinois on June 1-5, 2007:


ZADAXIN® (thymalfasin, thymosin alpha 1) Poster Presentation
A large first-line, randomized, dose-finding, phase II study on Thymosin alpha 1 (T?1) plus Dacarbazine (DTIC) with or without Interferon alpha (IFN?) vs DTIC plus IFN? in stage IV melanoma. Tumor response and survival results
(ASCO abstract number: 31541)

SCV-07 Abstract Proceedings
Effect of the Immune Modulating Peptide, SCV-07, in the Murine B16 Melanoma Model
(ASCO abstract number: 35151)

For further information about this conference, please visit www.asco.org.

About SciClone
SciClone Pharmaceuticals is a biopharmaceutical company engaged in the development of therapeutics to treat life-threatening diseases. SciClone's lead product ZADAXIN® is currently being evaluated in late-stage clinical trials for the treatment of malignant melanoma and hepatitis C. ZADAXIN is approved for sale in select markets internationally, most notably in China where SciClone has an established sales and marketing operation. A key part of SciClone's strategy is to leverage its advantage in the rapidly growing Chinese market by in-licensing or acquiring the marketing rights to other products, such as DC BeadTM, currently pending Chinese regulatory approval for the treatment of liver cancer. For the U.S. market, SciClone's clinical-stage drug development candidates are SCV-07 for the treatment of viral infectious diseases and RP101 for the treatment of pancreatic cancer. For more information about SciClone, visit www.sciclone.com.






Page: 1 2

Related medicine technology :

1. SciClone and Sigma-Tau Report Thymalfasin Meets Primary Endpoint in Phase 2 Malignant Melanoma Trial
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: SciClone Announces ZADAXIN and SCV Abstracts Accepted ASCO
(Date:1/15/2014)... , Jan. 15, 2014 As health ... of the flu virus, select Meijer pharmacies in ... for influenza and strep throat to eligible patients, enabling ... fill the matching prescriptions, under strict protocol set by ... Grand Rapids, Mich. -based retailer is ...
(Date:1/15/2014)... OAKS, Calif. , Jan. 15, 2014 /PRNewswire/ ... and Amgen (NASDAQ: AMGN ) announced ... to jointly discover and validate new therapeutic targets ... (IBD), a chronic disorder that affects millions worldwide. ... in clinical medicine, IBD biology, human genetics, genomic ...
(Date:1/15/2014)... 15, 2014  Manufacturers, suppliers and distributors ... be able to protect their most important ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) ... Medical Device Industry, it steadfastly remains one ... cases involving IP infringement. This litigious nature ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Intellectual Property Insurance for Medical-related Products and Services 2
... Oct. 29 Researchers at Thomas Jefferson University in Philadelphia, ... an article in the Journal of Nuclear Medicine reporting preclinical ... malignant breast tumors [1] . "All tumors ... targeted VPAC1 receptors located on the plasma membrane of the ...
... -- Shire plc (LSE: SHP, ... today that it will present key scientific data on its ... Extended Release Tablets, Vyvanse ®( ) (lisdexamfetamine ... (methylphenidate transdermal system) CII, at a national meeting of psychiatrists ...
Cached Medicine Technology:New Positron Emission Tomography (PET) Biomarker NVB-64 Visualizes Malignant Breast Tumors 2New Positron Emission Tomography (PET) Biomarker NVB-64 Visualizes Malignant Breast Tumors 3Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 2Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 3Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 4Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 5Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 6Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 7Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 8Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 9
(Date:3/9/2014)... Irritable bowel syndrome (IBS) belongs to the most ... sixty per cent of the workload of gastrointestinal ... IBS is bloating, which reduces quality of life ... For quite a long time, IBS was believed ... to this view, recent findings suggest that IBS ...
(Date:3/7/2014)... treatment for individuals with autism has been the focus ... these studies led the American Academy of Child and ... treating autism. Researchers led by Yale Child Study Center ... parameters in the Feb. issue of the Journal ... . , "Early diagnosis of children with autism ...
(Date:3/7/2014)... March 7, 2014 In association with ... Oncology (ASCO) has named Dr. Daniel D. Von ... 50 doctors who over the past half-century have ... Hoff, M.D., FACP, is Physician-In-Chief and Distinguished Professor ... Chief Scientific Officer for Scottsdale Healthcare,s Virginia G. ...
(Date:3/7/2014)... may have only had one glass of wine with dinner, ... hit you hard enough to make you a dangerous driver., ... party like you used to. , Sara Jo Nixon, Ph.D., ... the University of Florida and doctoral candidate Alfredo Sklar tested ... skills of two age groups: 36 people ages 25 to ...
(Date:3/7/2014)... TORONTO, March 7, 2014 -- A new study ... years of declining, the rates of teenagers coming ... dropping between 2006 and 2010. , Suicide-related behaviours ... Using data from the Institute for Clinical Evaluative ... 2006, the rates of teenagers coming into Ontario ...
Breaking Medicine News(10 mins):Health News:IBS and bloating: When the gut microbiota gets out of balance 2Health News:IBS and bloating: When the gut microbiota gets out of balance 3Health News:New guidelines employ a team approach to autism diagnosis and care 2Health News:TGen and Scottsdale Healthcare cancer expert Dr. Daniel D. Von Hoff is honored by ASCO 2Health News:For older drivers, study finds, 1 drink may be 1 too many 2Health News:For older drivers, study finds, 1 drink may be 1 too many 3Health News:After years of improving, rates of youth suicide-related behaviors stopped declining 2
... toll from the mosquito-borne virus has risen to six in ... died of the disease in the paediatric ward of King ... the Farrukhabad district hospital,' V.S. Nigam, health department spokesman told ... cases has shot up to 199 in the state with ...
... villager suffering from a serious kidney ailment died Saturday ... hospital here//, apparently because he could not afford the ... a window of the nephrology ward of the Sanjay ... was being treated, hospital sources told IANS. ...
... lowered cholesterol levels are beneficial for the heart is ... the risk of prostate cancer// for men has only ... convinced that the two conditions are related, proving that ... prostate, too. ,Dr. William J. Catalona, director of ...
... Nile virus evades the body’s immune defenses by blocking ... could pave the way for a vaccine// to protect ... Medical Center researchers report. ,Researchers discovered the receptor’s ... a study, described in October’s Journal of Virology that ...
... Although Offensive breath is a common malady that many suffer ... scenario. In an all out effort to overcome it those ... food stuffs, which are notably notorious in causing bad breath//. ... cover it up, chewing gums, and mouth rinses are usually ...
... caught between the devil and the deep sea, unable to ... of emergency mental// healthcare. The patient, a 17 year old ... form of counseling was attempted. ,The girl suffered ... suicide attempts. According to the mother, her daughter was ...
Cached Medicine News:Health News:Cholesterol Levels affects Risk of Prostate Cancer 2Health News:Study Unveils West Nile Virus Immune Evasion, Points to Vaccine Development 2Health News:Study Unveils West Nile Virus Immune Evasion, Points to Vaccine Development 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: